TAK
Takeda Pharmaceutical Company Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow -16.6% ·
net new positions +20.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 64.36K | $1.19M | +1 | −1 |
| Q2 2026 | 86 | +7 | 88.63M | $1.46B | +9 | −3 |
| Q1 2026 | 81 | +2 | 81.32M | $1.54B | +7 | −5 |
| Q4 2025 | 79 | -2 | 68.50M | $1.10B | n/a | −2 |
| Q3 2025 | 14 | +2 | 31.18M | $456.42M | +3 | −1 |
| Q2 2025 | 9 | -3 | 18.36M | $283.88M | n/a | −3 |
| Q1 2025 | 9 | +1 | 8.73M | $129.81M | +2 | −1 |
| Q4 2024 | 8 | +3 | 9.62M | $127.30M | +4 | −1 |
| Q3 2024 | 5 | 0 | 11.53M | $98.50M | +1 | −1 |
| Q2 2024 | 5 | n/a | 10.02M | $129.64M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Arrowstreet Capital ✦ | 4.22M | -9.0% | $55.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 3.08M | -4.3% | $40.77M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 3 | Millennium Management ✦ | 2.00M | -41.3% | $26.49M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 136.30K | -7.1% | $1.80M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 5 | Marshall Wace ✦ | 76.25K | New | $1.01M | 0.0% | New | 1 | SEC ↗ ×3 |
| 6 | Fisher Asset Management ✦ | 41.33K | New | $547,271 | 0.0% | New | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 37.99K | New | $502,974 | 0.0% | New | 1 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 26.60K | New | $352,184 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.01M | 0.0% |
| Fisher Asset Management | $547,271 | 0.0% |
| Citadel Advisors | $502,974 | 0.0% |
| Point72 Asset Management | $352,184 | 0.0% |
Exited
| D. E. Shaw & Co. | $1.74M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 356 holders, 97.72M shares, $1.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 34.53K sh · $640,279
Officer, Director · 19.65K sh · $363,347
Officer · 12.98K sh · $235,118
Officer · 47.59K sh · $813,721
Officer · 14.01K sh · $239,503
Officer · 30.87K sh · $527,843
Officer · 975 sh · $17,062
Officer · 33.63K sh · $588,715
Officer · 6.77K sh · $115,835
Officer · 50.01K sh · $855,205
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology